HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer
Public ClinicalTrials.gov record NCT05553639. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of Replicating Arenavirus-based Vector(s) Encoding Prostate Cancer-Associated Antigens in Participants With Metastatic Castration-Resistant Prostate Cancer
Study identification
- NCT ID
- NCT05553639
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Hookipa Biotech GmbH
- Industry
- Enrollment
- 12 participants
Conditions and interventions
Conditions
Interventions
- HB-302/HB-301 Alternating 2-Vector Therapy Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 22, 2023
- Primary completion
- Apr 28, 2024
- Completion
- Apr 28, 2024
- Last update posted
- Jun 11, 2024
2023 – 2024
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | — |
| California Cancer Associates for Research & Excellence (cCARE) | San Marcos | California | 92069 | — |
| University of Miami - Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Miami Cancer Institute | Miami | Florida | 33176 | — |
| Emory University Hospital | Atlanta | Georgia | 30322 | — |
| The Cancer Institute of New Jersey CINJ Rutgers | New Brunswick | New Jersey | 08901 | — |
| Columbia University Irving Medical Center | New York | New York | 10032 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Providence Cancer Institute | Portland | Oregon | 97213 | — |
| Thompson Cancer Survival Center | Knoxville | Tennessee | 37916 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05553639, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 11, 2024 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05553639 live on ClinicalTrials.gov.